Diffusion-weighted magnetic resonance imaging in non-invasive monitoring of antiangiogenic therapy in experimental tumor model

Exp Oncol. 2010 Jul;32(2):104-6.


Aim: To show usefulness of diffusion-weighted magnetic resonance imaging (MRI) for non-invasive assessment of experimental tumor after antiangiogenic treatment.

Methods: M1 sarcoma was implanted to the peritoneal cavity of the rat and allowed to grow to a palpable tumor size. Animal was treated with a single injection of endothelial growth factor antibody Bevacizumab (Avastin). Serial MRI scanning including diffusion-weighted sequence was performed before and up to 100 h after treatment. Animal was sacrificed thereafter and MRI data were correlated with morphology.

Results: Apparent diffusion coefficient (ADC) maps derived tumor necrotic area correlated well with histology-derived tumor necrotic area. ADC threshold of 1.39 x 10(-3) mm(2)/s appeared to be optimal for tumor necrosis quantification in this tumor model and allowed to follow temporal changes of tumor internal structure after treatment.

Conclusion: Diffusion-weighted MRI permits non-invasive tissue characterization without the need for exogenous contrast agents and, therefore, may be used to individualise therapy and to monitor tumor response.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Diffusion Magnetic Resonance Imaging
  • Neoplasms, Experimental / drug therapy*
  • Neoplasms, Experimental / pathology*
  • Rats


  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab